Two analyses of French registry data showed the urgent need for a head-to-head randomized trial of the newest transcatheter aortic valve replacement (TAVR) systems, according to the studies’ authors.
A matched-propensity analysis of 12,141 patients in the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?